nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—EGFR—bone cancer	0.55	0.732	CbGaD
Lidocaine—CYP3A4—bone cancer	0.201	0.268	CbGaD
Lidocaine—CYP2B6—Cisplatin—bone cancer	0.0168	0.255	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—bone cancer	0.0112	0.171	CbGbCtD
Lidocaine—CYP2C9—Cisplatin—bone cancer	0.00886	0.135	CbGbCtD
Lidocaine—ABCB1—Cisplatin—bone cancer	0.0086	0.131	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—bone cancer	0.00576	0.0877	CbGbCtD
Lidocaine—ABCB1—Methotrexate—bone cancer	0.00558	0.085	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—bone cancer	0.00543	0.0826	CbGbCtD
Lidocaine—Apprehension—Cisplatin—bone cancer	0.00422	0.0424	CcSEcCtD
Lidocaine—Cranial nerve paralysis—Methotrexate—bone cancer	0.00386	0.0387	CcSEcCtD
Lidocaine—CNS toxicity—Methotrexate—bone cancer	0.00386	0.0387	CcSEcCtD
Lidocaine—CYP3A4—Doxorubicin—bone cancer	0.00345	0.0525	CbGbCtD
Lidocaine—Neurological symptom—Cisplatin—bone cancer	0.00268	0.0269	CcSEcCtD
Lidocaine—Meningism—Methotrexate—bone cancer	0.00256	0.0257	CcSEcCtD
Lidocaine—Arachnoiditis—Methotrexate—bone cancer	0.00243	0.0244	CcSEcCtD
Lidocaine—Neurotoxicity—Cisplatin—bone cancer	0.00209	0.021	CcSEcCtD
Lidocaine—Slurred speech—Cisplatin—bone cancer	0.00181	0.0182	CcSEcCtD
Lidocaine—Taste metallic—Methotrexate—bone cancer	0.0014	0.014	CcSEcCtD
Lidocaine—Neurotoxicity—Methotrexate—bone cancer	0.00115	0.0115	CcSEcCtD
Lidocaine—Neurotoxicity—Epirubicin—bone cancer	0.00107	0.0108	CcSEcCtD
Lidocaine—Leukoderma—Methotrexate—bone cancer	0.00105	0.0105	CcSEcCtD
Lidocaine—Neurotoxicity—Doxorubicin—bone cancer	0.000992	0.00997	CcSEcCtD
Lidocaine—Leukoderma—Epirubicin—bone cancer	0.000978	0.00982	CcSEcCtD
Lidocaine—Levobupivacaine—CYP3A4—bone cancer	0.000946	0.409	CrCbGaD
Lidocaine—Tenderness—Cisplatin—bone cancer	0.000928	0.00932	CcSEcCtD
Lidocaine—Leukoderma—Doxorubicin—bone cancer	0.000905	0.00909	CcSEcCtD
Lidocaine—Dysarthria—Cisplatin—bone cancer	0.000856	0.0086	CcSEcCtD
Lidocaine—Pain—Carboplatin—bone cancer	0.000842	0.00846	CcSEcCtD
Lidocaine—Skin exfoliation—Cisplatin—bone cancer	0.000773	0.00776	CcSEcCtD
Lidocaine—Neuropathy—Cisplatin—bone cancer	0.00076	0.00764	CcSEcCtD
Lidocaine—Bupivacaine—CYP3A4—bone cancer	0.000757	0.327	CrCbGaD
Lidocaine—Local reaction—Epirubicin—bone cancer	0.000751	0.00754	CcSEcCtD
Lidocaine—Local reaction—Doxorubicin—bone cancer	0.000695	0.00698	CcSEcCtD
Lidocaine—Paralysis—Methotrexate—bone cancer	0.00064	0.00642	CcSEcCtD
Lidocaine—Burning sensation—Methotrexate—bone cancer	0.00064	0.00642	CcSEcCtD
Lidocaine—Redness—Epirubicin—bone cancer	0.000616	0.00619	CcSEcCtD
Lidocaine—Ropivacaine—CYP3A4—bone cancer	0.00061	0.264	CrCbGaD
Lidocaine—Anaphylactoid reaction—Cisplatin—bone cancer	0.000607	0.0061	CcSEcCtD
Lidocaine—Paralysis—Epirubicin—bone cancer	0.000599	0.00601	CcSEcCtD
Lidocaine—Burning sensation—Epirubicin—bone cancer	0.000599	0.00601	CcSEcCtD
Lidocaine—Blister—Epirubicin—bone cancer	0.000577	0.00579	CcSEcCtD
Lidocaine—Redness—Doxorubicin—bone cancer	0.00057	0.00572	CcSEcCtD
Lidocaine—Gingivitis—Methotrexate—bone cancer	0.000566	0.00569	CcSEcCtD
Lidocaine—Paralysis—Doxorubicin—bone cancer	0.000554	0.00556	CcSEcCtD
Lidocaine—Burning sensation—Doxorubicin—bone cancer	0.000554	0.00556	CcSEcCtD
Lidocaine—Petechiae—Methotrexate—bone cancer	0.00054	0.00542	CcSEcCtD
Lidocaine—Blister—Doxorubicin—bone cancer	0.000534	0.00536	CcSEcCtD
Lidocaine—Hyperaesthesia—Epirubicin—bone cancer	0.00053	0.00532	CcSEcCtD
Lidocaine—Feeling hot—Epirubicin—bone cancer	0.00053	0.00532	CcSEcCtD
Lidocaine—Gingivitis—Epirubicin—bone cancer	0.00053	0.00532	CcSEcCtD
Lidocaine—Apnoea—Methotrexate—bone cancer	0.000524	0.00526	CcSEcCtD
Lidocaine—Petechiae—Epirubicin—bone cancer	0.000506	0.00508	CcSEcCtD
Lidocaine—Dysphonia—Epirubicin—bone cancer	0.000506	0.00508	CcSEcCtD
Lidocaine—Sweating increased—Cisplatin—bone cancer	0.000495	0.00497	CcSEcCtD
Lidocaine—Gingivitis—Doxorubicin—bone cancer	0.00049	0.00492	CcSEcCtD
Lidocaine—Hyperaesthesia—Doxorubicin—bone cancer	0.00049	0.00492	CcSEcCtD
Lidocaine—Feeling hot—Doxorubicin—bone cancer	0.00049	0.00492	CcSEcCtD
Lidocaine—Dysarthria—Methotrexate—bone cancer	0.00047	0.00472	CcSEcCtD
Lidocaine—Petechiae—Doxorubicin—bone cancer	0.000468	0.0047	CcSEcCtD
Lidocaine—Dysphonia—Doxorubicin—bone cancer	0.000468	0.0047	CcSEcCtD
Lidocaine—Neuropathy peripheral—Cisplatin—bone cancer	0.000444	0.00446	CcSEcCtD
Lidocaine—Stomatitis—Cisplatin—bone cancer	0.000442	0.00443	CcSEcCtD
Lidocaine—Dysarthria—Epirubicin—bone cancer	0.00044	0.00442	CcSEcCtD
Lidocaine—Depressed level of consciousness—Methotrexate—bone cancer	0.000429	0.00431	CcSEcCtD
Lidocaine—Atrioventricular block—Epirubicin—bone cancer	0.000429	0.00431	CcSEcCtD
Lidocaine—Skin exfoliation—Methotrexate—bone cancer	0.000424	0.00426	CcSEcCtD
Lidocaine—Ventricular tachycardia—Epirubicin—bone cancer	0.000416	0.00418	CcSEcCtD
Lidocaine—Bradycardia—Cisplatin—bone cancer	0.000414	0.00416	CcSEcCtD
Lidocaine—Dermatitis contact—Epirubicin—bone cancer	0.000411	0.00413	CcSEcCtD
Lidocaine—Dysarthria—Doxorubicin—bone cancer	0.000407	0.00409	CcSEcCtD
Lidocaine—Coma—Methotrexate—bone cancer	0.000406	0.00408	CcSEcCtD
Lidocaine—Skin exfoliation—Epirubicin—bone cancer	0.000397	0.00399	CcSEcCtD
Lidocaine—Atrioventricular block—Doxorubicin—bone cancer	0.000397	0.00398	CcSEcCtD
Lidocaine—Visual impairment—Cisplatin—bone cancer	0.000392	0.00394	CcSEcCtD
Lidocaine—Neuropathy—Epirubicin—bone cancer	0.00039	0.00392	CcSEcCtD
Lidocaine—Ventricular tachycardia—Doxorubicin—bone cancer	0.000385	0.00386	CcSEcCtD
Lidocaine—Dermatitis contact—Doxorubicin—bone cancer	0.00038	0.00382	CcSEcCtD
Lidocaine—Eye disorder—Cisplatin—bone cancer	0.00038	0.00382	CcSEcCtD
Lidocaine—Coma—Epirubicin—bone cancer	0.00038	0.00382	CcSEcCtD
Lidocaine—Tinnitus—Cisplatin—bone cancer	0.000379	0.00381	CcSEcCtD
Lidocaine—Cardiac disorder—Cisplatin—bone cancer	0.000377	0.00379	CcSEcCtD
Lidocaine—Flushing—Cisplatin—bone cancer	0.000377	0.00379	CcSEcCtD
Lidocaine—Skin exfoliation—Doxorubicin—bone cancer	0.000367	0.00369	CcSEcCtD
Lidocaine—Immune system disorder—Cisplatin—bone cancer	0.000367	0.00369	CcSEcCtD
Lidocaine—Neuropathy—Doxorubicin—bone cancer	0.000361	0.00363	CcSEcCtD
Lidocaine—Erythema—Cisplatin—bone cancer	0.000354	0.00356	CcSEcCtD
Lidocaine—Coma—Doxorubicin—bone cancer	0.000352	0.00353	CcSEcCtD
Lidocaine—Visual disturbance—Methotrexate—bone cancer	0.00034	0.00342	CcSEcCtD
Lidocaine—Vision blurred—Cisplatin—bone cancer	0.000334	0.00335	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Methotrexate—bone cancer	0.000333	0.00335	CcSEcCtD
Lidocaine—Tremor—Cisplatin—bone cancer	0.000332	0.00333	CcSEcCtD
Lidocaine—Osteoarthritis—Methotrexate—bone cancer	0.000323	0.00324	CcSEcCtD
Lidocaine—Dermatitis bullous—Epirubicin—bone cancer	0.000316	0.00317	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Epirubicin—bone cancer	0.000312	0.00313	CcSEcCtD
Lidocaine—Convulsion—Cisplatin—bone cancer	0.000307	0.00308	CcSEcCtD
Lidocaine—Osteoarthritis—Epirubicin—bone cancer	0.000302	0.00303	CcSEcCtD
Lidocaine—Diplopia—Epirubicin—bone cancer	0.000302	0.00303	CcSEcCtD
Lidocaine—Anxiety—Cisplatin—bone cancer	0.0003	0.00302	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—bone cancer	0.000292	0.00293	CcSEcCtD
Lidocaine—Anaphylactic shock—Cisplatin—bone cancer	0.000289	0.0029	CcSEcCtD
Lidocaine—Oedema—Cisplatin—bone cancer	0.000289	0.0029	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000289	0.0029	CcSEcCtD
Lidocaine—Cardiac arrest—Epirubicin—bone cancer	0.000287	0.00288	CcSEcCtD
Lidocaine—Nervous system disorder—Cisplatin—bone cancer	0.000283	0.00285	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—bone cancer	0.000279	0.00281	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—bone cancer	0.000279	0.00281	CcSEcCtD
Lidocaine—Hyperhidrosis—Cisplatin—bone cancer	0.000279	0.0028	CcSEcCtD
Lidocaine—Asthma—Methotrexate—bone cancer	0.000279	0.0028	CcSEcCtD
Lidocaine—Hypotension—Cisplatin—bone cancer	0.00027	0.00271	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—bone cancer	0.000266	0.00267	CcSEcCtD
Lidocaine—Dysphagia—Epirubicin—bone cancer	0.000261	0.00262	CcSEcCtD
Lidocaine—Asthma—Epirubicin—bone cancer	0.000261	0.00262	CcSEcCtD
Lidocaine—Paraesthesia—Cisplatin—bone cancer	0.000259	0.00261	CcSEcCtD
Lidocaine—Dyspnoea—Cisplatin—bone cancer	0.000258	0.00259	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000249	0.0025	CcSEcCtD
Lidocaine—Drowsiness—Methotrexate—bone cancer	0.000249	0.0025	CcSEcCtD
Lidocaine—Pain—Cisplatin—bone cancer	0.000247	0.00248	CcSEcCtD
Lidocaine—Stomatitis—Methotrexate—bone cancer	0.000242	0.00243	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—bone cancer	0.000241	0.00242	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—bone cancer	0.000241	0.00242	CcSEcCtD
Lidocaine—Feeling abnormal—Cisplatin—bone cancer	0.000238	0.00239	CcSEcCtD
Lidocaine—Drowsiness—Epirubicin—bone cancer	0.000233	0.00234	CcSEcCtD
Lidocaine—Neuropathy peripheral—Epirubicin—bone cancer	0.000228	0.00229	CcSEcCtD
Lidocaine—Stomatitis—Epirubicin—bone cancer	0.000227	0.00228	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—bone cancer	0.000224	0.00225	CcSEcCtD
Lidocaine—Haemorrhage—Methotrexate—bone cancer	0.000223	0.00224	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—bone cancer	0.000215	0.00216	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—bone cancer	0.000215	0.00216	CcSEcCtD
Lidocaine—Hypersensitivity—Cisplatin—bone cancer	0.000213	0.00214	CcSEcCtD
Lidocaine—Bradycardia—Epirubicin—bone cancer	0.000213	0.00214	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000211	0.00212	CcSEcCtD
Lidocaine—Haemoglobin—Epirubicin—bone cancer	0.00021	0.00211	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—bone cancer	0.00021	0.00211	CcSEcCtD
Lidocaine—Rhinitis—Epirubicin—bone cancer	0.000209	0.0021	CcSEcCtD
Lidocaine—Haemorrhage—Epirubicin—bone cancer	0.000209	0.0021	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—bone cancer	0.000209	0.00209	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—bone cancer	0.000208	0.00209	CcSEcCtD
Lidocaine—Hypoaesthesia—Epirubicin—bone cancer	0.000208	0.00209	CcSEcCtD
Lidocaine—Asthenia—Cisplatin—bone cancer	0.000207	0.00208	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—bone cancer	0.000207	0.00208	CcSEcCtD
Lidocaine—Angiopathy—Methotrexate—bone cancer	0.000202	0.00203	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—bone cancer	0.000202	0.00202	CcSEcCtD
Lidocaine—Visual impairment—Epirubicin—bone cancer	0.000201	0.00202	CcSEcCtD
Lidocaine—Chills—Methotrexate—bone cancer	0.0002	0.00201	CcSEcCtD
Lidocaine—Bradycardia—Doxorubicin—bone cancer	0.000197	0.00198	CcSEcCtD
Lidocaine—Eye disorder—Epirubicin—bone cancer	0.000195	0.00196	CcSEcCtD
Lidocaine—Tinnitus—Epirubicin—bone cancer	0.000195	0.00196	CcSEcCtD
Lidocaine—Erythema—Methotrexate—bone cancer	0.000194	0.00195	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—bone cancer	0.000194	0.00195	CcSEcCtD
Lidocaine—Cardiac disorder—Epirubicin—bone cancer	0.000194	0.00195	CcSEcCtD
Lidocaine—Flushing—Epirubicin—bone cancer	0.000194	0.00195	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—bone cancer	0.000194	0.00195	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—bone cancer	0.000193	0.00194	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—bone cancer	0.000192	0.00193	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—bone cancer	0.00019	0.00191	CcSEcCtD
Lidocaine—Angiopathy—Epirubicin—bone cancer	0.000189	0.0019	CcSEcCtD
Lidocaine—Immune system disorder—Epirubicin—bone cancer	0.000189	0.00189	CcSEcCtD
Lidocaine—Back pain—Methotrexate—bone cancer	0.000188	0.00189	CcSEcCtD
Lidocaine—Chills—Epirubicin—bone cancer	0.000187	0.00188	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—bone cancer	0.000186	0.00187	CcSEcCtD
Lidocaine—Vomiting—Cisplatin—bone cancer	0.000184	0.00184	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—bone cancer	0.000183	0.00184	CcSEcCtD
Lidocaine—Rash—Cisplatin—bone cancer	0.000182	0.00183	CcSEcCtD
Lidocaine—Dermatitis—Cisplatin—bone cancer	0.000182	0.00183	CcSEcCtD
Lidocaine—Erythema—Epirubicin—bone cancer	0.000182	0.00183	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—bone cancer	0.000181	0.00181	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—bone cancer	0.00018	0.00181	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—bone cancer	0.000179	0.0018	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—bone cancer	0.000179	0.0018	CcSEcCtD
Lidocaine—Tension—Epirubicin—bone cancer	0.000178	0.00179	CcSEcCtD
Lidocaine—Dysgeusia—Epirubicin—bone cancer	0.000178	0.00179	CcSEcCtD
Lidocaine—Nervousness—Epirubicin—bone cancer	0.000177	0.00177	CcSEcCtD
Lidocaine—Back pain—Epirubicin—bone cancer	0.000176	0.00177	CcSEcCtD
Lidocaine—Angiopathy—Doxorubicin—bone cancer	0.000175	0.00176	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—bone cancer	0.000175	0.00175	CcSEcCtD
Lidocaine—Chills—Doxorubicin—bone cancer	0.000173	0.00174	CcSEcCtD
Lidocaine—Nausea—Cisplatin—bone cancer	0.000172	0.00172	CcSEcCtD
Lidocaine—Vision blurred—Epirubicin—bone cancer	0.000171	0.00172	CcSEcCtD
Lidocaine—Convulsion—Methotrexate—bone cancer	0.000168	0.00169	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—bone cancer	0.000168	0.00169	CcSEcCtD
Lidocaine—Agitation—Epirubicin—bone cancer	0.000167	0.00168	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—bone cancer	0.000165	0.00166	CcSEcCtD
Lidocaine—Tension—Doxorubicin—bone cancer	0.000165	0.00166	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—bone cancer	0.000165	0.00165	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—bone cancer	0.000163	0.00164	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—bone cancer	0.000163	0.00163	CcSEcCtD
Lidocaine—Confusional state—Methotrexate—bone cancer	0.00016	0.00161	CcSEcCtD
Lidocaine—Loss of consciousness—Epirubicin—bone cancer	0.00016	0.0016	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—bone cancer	0.000159	0.00159	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—bone cancer	0.000159	0.00159	CcSEcCtD
Lidocaine—Convulsion—Epirubicin—bone cancer	0.000158	0.00158	CcSEcCtD
Lidocaine—Hypertension—Epirubicin—bone cancer	0.000157	0.00158	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—bone cancer	0.000155	0.00156	CcSEcCtD
Lidocaine—Chest pain—Epirubicin—bone cancer	0.000155	0.00155	CcSEcCtD
Lidocaine—Agitation—Doxorubicin—bone cancer	0.000155	0.00155	CcSEcCtD
Lidocaine—Anxiety—Epirubicin—bone cancer	0.000154	0.00155	CcSEcCtD
Lidocaine—Hyperhidrosis—Methotrexate—bone cancer	0.000153	0.00154	CcSEcCtD
Lidocaine—Confusional state—Epirubicin—bone cancer	0.00015	0.0015	CcSEcCtD
Lidocaine—Oedema—Epirubicin—bone cancer	0.000148	0.00149	CcSEcCtD
Lidocaine—Anaphylactic shock—Epirubicin—bone cancer	0.000148	0.00149	CcSEcCtD
Lidocaine—Hypotension—Methotrexate—bone cancer	0.000148	0.00149	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—bone cancer	0.000148	0.00148	CcSEcCtD
Lidocaine—Shock—Epirubicin—bone cancer	0.000146	0.00147	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—bone cancer	0.000146	0.00146	CcSEcCtD
Lidocaine—Nervous system disorder—Epirubicin—bone cancer	0.000146	0.00146	CcSEcCtD
Lidocaine—Hypertension—Doxorubicin—bone cancer	0.000145	0.00146	CcSEcCtD
Lidocaine—Hyperhidrosis—Epirubicin—bone cancer	0.000143	0.00144	CcSEcCtD
Lidocaine—Chest pain—Doxorubicin—bone cancer	0.000143	0.00144	CcSEcCtD
Lidocaine—Anxiety—Doxorubicin—bone cancer	0.000143	0.00143	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—bone cancer	0.000142	0.00143	CcSEcCtD
Lidocaine—Dyspnoea—Methotrexate—bone cancer	0.000141	0.00142	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—bone cancer	0.000141	0.00142	CcSEcCtD
Lidocaine—Hypotension—Epirubicin—bone cancer	0.000139	0.00139	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—bone cancer	0.000138	0.00139	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—bone cancer	0.000137	0.00138	CcSEcCtD
Lidocaine—Anaphylactic shock—Doxorubicin—bone cancer	0.000137	0.00138	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000137	0.00137	CcSEcCtD
Lidocaine—Pain—Methotrexate—bone cancer	0.000136	0.00136	CcSEcCtD
Lidocaine—Shock—Doxorubicin—bone cancer	0.000135	0.00136	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—bone cancer	0.000135	0.00135	CcSEcCtD
Lidocaine—Paraesthesia—Epirubicin—bone cancer	0.000133	0.00134	CcSEcCtD
Lidocaine—Hyperhidrosis—Doxorubicin—bone cancer	0.000133	0.00133	CcSEcCtD
Lidocaine—Dyspnoea—Epirubicin—bone cancer	0.000132	0.00133	CcSEcCtD
Lidocaine—Somnolence—Epirubicin—bone cancer	0.000132	0.00132	CcSEcCtD
Lidocaine—Feeling abnormal—Methotrexate—bone cancer	0.000131	0.00131	CcSEcCtD
Lidocaine—Hypotension—Doxorubicin—bone cancer	0.000128	0.00129	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000128	0.00129	CcSEcCtD
Lidocaine—Pain—Epirubicin—bone cancer	0.000127	0.00127	CcSEcCtD
Lidocaine—Urticaria—Methotrexate—bone cancer	0.000126	0.00126	CcSEcCtD
Lidocaine—Paraesthesia—Doxorubicin—bone cancer	0.000123	0.00124	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—bone cancer	0.000122	0.00123	CcSEcCtD
Lidocaine—Feeling abnormal—Epirubicin—bone cancer	0.000122	0.00123	CcSEcCtD
Lidocaine—Somnolence—Doxorubicin—bone cancer	0.000122	0.00123	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000119	0.00119	CcSEcCtD
Lidocaine—Urticaria—Epirubicin—bone cancer	0.000118	0.00118	CcSEcCtD
Lidocaine—Pain—Doxorubicin—bone cancer	0.000117	0.00118	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—bone cancer	0.000117	0.00117	CcSEcCtD
Lidocaine—Asthenia—Methotrexate—bone cancer	0.000114	0.00114	CcSEcCtD
Lidocaine—Feeling abnormal—Doxorubicin—bone cancer	0.000113	0.00114	CcSEcCtD
Lidocaine—Hypersensitivity—Epirubicin—bone cancer	0.000109	0.0011	CcSEcCtD
Lidocaine—Urticaria—Doxorubicin—bone cancer	0.000109	0.0011	CcSEcCtD
Lidocaine—Asthenia—Epirubicin—bone cancer	0.000106	0.00107	CcSEcCtD
Lidocaine—Dizziness—Methotrexate—bone cancer	0.000105	0.00105	CcSEcCtD
Lidocaine—Hypersensitivity—Doxorubicin—bone cancer	0.000101	0.00102	CcSEcCtD
Lidocaine—Vomiting—Methotrexate—bone cancer	0.000101	0.00101	CcSEcCtD
Lidocaine—Rash—Methotrexate—bone cancer	0.0001	0.001	CcSEcCtD
Lidocaine—Dermatitis—Methotrexate—bone cancer	9.99e-05	0.001	CcSEcCtD
Lidocaine—Headache—Methotrexate—bone cancer	9.93e-05	0.000997	CcSEcCtD
Lidocaine—Asthenia—Doxorubicin—bone cancer	9.85e-05	0.000989	CcSEcCtD
Lidocaine—Dizziness—Epirubicin—bone cancer	9.81e-05	0.000985	CcSEcCtD
Lidocaine—Vomiting—Epirubicin—bone cancer	9.43e-05	0.000947	CcSEcCtD
Lidocaine—Nausea—Methotrexate—bone cancer	9.42e-05	0.000946	CcSEcCtD
Lidocaine—Rash—Epirubicin—bone cancer	9.36e-05	0.000939	CcSEcCtD
Lidocaine—Dermatitis—Epirubicin—bone cancer	9.35e-05	0.000939	CcSEcCtD
Lidocaine—Headache—Epirubicin—bone cancer	9.3e-05	0.000933	CcSEcCtD
Lidocaine—Dizziness—Doxorubicin—bone cancer	9.08e-05	0.000912	CcSEcCtD
Lidocaine—Nausea—Epirubicin—bone cancer	8.81e-05	0.000885	CcSEcCtD
Lidocaine—Vomiting—Doxorubicin—bone cancer	8.73e-05	0.000877	CcSEcCtD
Lidocaine—Rash—Doxorubicin—bone cancer	8.66e-05	0.000869	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—bone cancer	8.65e-05	0.000868	CcSEcCtD
Lidocaine—Headache—Doxorubicin—bone cancer	8.6e-05	0.000864	CcSEcCtD
Lidocaine—Nausea—Doxorubicin—bone cancer	8.15e-05	0.000819	CcSEcCtD
Lidocaine—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—bone cancer	7.22e-05	0.000888	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—KIT—bone cancer	7.22e-05	0.000887	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	7.21e-05	0.000887	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—BRAF—bone cancer	7.2e-05	0.000885	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—KIT—bone cancer	7.18e-05	0.000884	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—NDUFA12—bone cancer	7.14e-05	0.000879	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—MMP9—bone cancer	7.07e-05	0.00087	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—MMP2—bone cancer	7.02e-05	0.000863	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—MDM2—bone cancer	6.98e-05	0.000858	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—MDM2—bone cancer	6.94e-05	0.000853	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—BRAF—bone cancer	6.91e-05	0.000849	CbGpPWpGaD
Lidocaine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.85e-05	0.000843	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—KIT—bone cancer	6.8e-05	0.000836	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—MMP9—bone cancer	6.8e-05	0.000836	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—MMP9—bone cancer	6.8e-05	0.000836	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—MMP9—bone cancer	6.77e-05	0.000832	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—MMP2—bone cancer	6.72e-05	0.000826	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—MDM2—bone cancer	6.64e-05	0.000817	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	6.6e-05	0.000812	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—MDM2—bone cancer	6.57e-05	0.000808	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.56e-05	0.000807	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—MMP9—bone cancer	6.55e-05	0.000806	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—NDUFA12—bone cancer	6.55e-05	0.000805	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—MDM2—bone cancer	6.54e-05	0.000804	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—BRAF—bone cancer	6.52e-05	0.000802	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	6.51e-05	0.0008	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—MMP2—bone cancer	6.45e-05	0.000793	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—MMP2—bone cancer	6.45e-05	0.000793	CbGpPWpGaD
Lidocaine—CYP2C8—Biological oxidations—GSTP1—bone cancer	6.38e-05	0.000785	CbGpPWpGaD
Lidocaine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	6.29e-05	0.000774	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—MDM2—bone cancer	6.24e-05	0.000768	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—MMP2—bone cancer	6.22e-05	0.000765	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—MDM2—bone cancer	6.21e-05	0.000764	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—MDM2—bone cancer	6.18e-05	0.00076	CbGpPWpGaD
Lidocaine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.18e-05	0.00076	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—GRM4—bone cancer	6.16e-05	0.000757	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—RGS1—bone cancer	6.16e-05	0.000757	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—MDM2—bone cancer	6.15e-05	0.000756	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways in Glioblastoma—TP53—bone cancer	6.14e-05	0.000756	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—MMP2—bone cancer	6.13e-05	0.000754	CbGpPWpGaD
Lidocaine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.13e-05	0.000753	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	6.12e-05	0.000752	CbGpPWpGaD
Lidocaine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	6.07e-05	0.000747	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—JUN—bone cancer	6.07e-05	0.000746	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	6.06e-05	0.000745	CbGpPWpGaD
Lidocaine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.04e-05	0.000743	CbGpPWpGaD
Lidocaine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.99e-05	0.000737	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.98e-05	0.000735	CbGpPWpGaD
Lidocaine—SCN9A—Axon guidance—EGFR—bone cancer	5.98e-05	0.000735	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.95e-05	0.000732	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—NT5C3A—bone cancer	5.92e-05	0.000728	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.9e-05	0.000725	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—MMP9—bone cancer	5.87e-05	0.000722	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	5.79e-05	0.000711	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—MDM2—bone cancer	5.79e-05	0.000711	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—MDM2—bone cancer	5.79e-05	0.000711	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—MDM2—bone cancer	5.73e-05	0.000705	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—EGFR—bone cancer	5.72e-05	0.000703	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—JUN—bone cancer	5.71e-05	0.000702	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—MDM2—bone cancer	5.68e-05	0.000699	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—MDM2—bone cancer	5.66e-05	0.000696	CbGpPWpGaD
Lidocaine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.59e-05	0.000687	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—EGFR—bone cancer	5.49e-05	0.000675	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—EGFR—bone cancer	5.49e-05	0.000675	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.44e-05	0.000669	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—NT5C3A—bone cancer	5.43e-05	0.000667	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—JUN—bone cancer	5.4e-05	0.000664	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—MDM2—bone cancer	5.35e-05	0.000658	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—GRM1—bone cancer	5.34e-05	0.000656	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—EGFR—bone cancer	5.3e-05	0.000651	CbGpPWpGaD
Lidocaine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.29e-05	0.00065	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—NDUFA12—bone cancer	5.28e-05	0.00065	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—MMP9—bone cancer	5.28e-05	0.000649	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.25e-05	0.000645	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—CDK4—bone cancer	5.24e-05	0.000645	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MET—bone cancer	5.24e-05	0.000645	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—JUN—bone cancer	5.24e-05	0.000645	CbGpPWpGaD
Lidocaine—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.24e-05	0.000644	CbGpPWpGaD
Lidocaine—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.19e-05	0.000639	CbGpPWpGaD
Lidocaine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.19e-05	0.000638	CbGpPWpGaD
Lidocaine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.17e-05	0.000635	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NDUFA12—bone cancer	5.16e-05	0.000635	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	5.12e-05	0.00063	CbGpPWpGaD
Lidocaine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.12e-05	0.00063	CbGpPWpGaD
Lidocaine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	5.12e-05	0.000629	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—MMP9—bone cancer	5.05e-05	0.000621	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	5.03e-05	0.000618	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—ATF1—bone cancer	5.02e-05	0.000617	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—KIT—bone cancer	5e-05	0.000615	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5e-05	0.000615	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.98e-05	0.000613	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—MMP9—bone cancer	4.85e-05	0.000596	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—MMP9—bone cancer	4.85e-05	0.000596	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—MET—bone cancer	4.81e-05	0.000592	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—JUN—bone cancer	4.75e-05	0.000584	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.73e-05	0.000582	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—BRAF—bone cancer	4.7e-05	0.000578	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.68e-05	0.000576	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.68e-05	0.000576	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—MMP9—bone cancer	4.68e-05	0.000575	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—MMP9—bone cancer	4.61e-05	0.000567	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—TP53—bone cancer	4.59e-05	0.000565	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NDUFA12—bone cancer	4.47e-05	0.00055	CbGpPWpGaD
Lidocaine—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.44e-05	0.000546	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—NT5C3A—bone cancer	4.38e-05	0.000538	CbGpPWpGaD
Lidocaine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.38e-05	0.000538	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MMP2—bone cancer	4.37e-05	0.000538	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.3e-05	0.000529	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NT5C3A—bone cancer	4.28e-05	0.000526	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—EGFR—bone cancer	4.26e-05	0.000524	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—EGFR—bone cancer	4.08e-05	0.000502	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—MMP2—bone cancer	4.01e-05	0.000494	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—TP53—bone cancer	4e-05	0.000492	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—MDM2—bone cancer	3.94e-05	0.000485	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—EGFR—bone cancer	3.92e-05	0.000482	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—EGFR—bone cancer	3.92e-05	0.000482	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—ENO2—bone cancer	3.9e-05	0.00048	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NDUFA12—bone cancer	3.9e-05	0.000479	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—EGFR—bone cancer	3.78e-05	0.000465	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—TP53—bone cancer	3.77e-05	0.000464	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—SMO—bone cancer	3.76e-05	0.000462	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—EGFR—bone cancer	3.72e-05	0.000458	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.71e-05	0.000456	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NT5C3A—bone cancer	3.71e-05	0.000456	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NDUFA12—bone cancer	3.67e-05	0.000452	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NDUFA12—bone cancer	3.64e-05	0.000448	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—GRM4—bone cancer	3.64e-05	0.000447	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RGS1—bone cancer	3.64e-05	0.000447	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—DHFR—bone cancer	3.62e-05	0.000445	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—TP53—bone cancer	3.46e-05	0.000426	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—GNA11—bone cancer	3.44e-05	0.000423	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—CDK4—bone cancer	3.43e-05	0.000422	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MET—bone cancer	3.43e-05	0.000422	CbGpPWpGaD
Lidocaine—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.43e-05	0.000421	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—GNA11—bone cancer	3.38e-05	0.000416	CbGpPWpGaD
Lidocaine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.38e-05	0.000415	CbGpPWpGaD
Lidocaine—EGFR—Disease—ENO2—bone cancer	3.35e-05	0.000411	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MMP9—bone cancer	3.29e-05	0.000404	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NT5C3A—bone cancer	3.23e-05	0.000397	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—GRM1—bone cancer	3.15e-05	0.000388	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.12e-05	0.000384	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL3—bone cancer	3.12e-05	0.000383	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NDUFA12—bone cancer	3.11e-05	0.000383	CbGpPWpGaD
Lidocaine—EGFR—Disease—DHFR—bone cancer	3.1e-05	0.000382	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—CYP3A4—bone cancer	3.07e-05	0.000377	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NT5C3A—bone cancer	3.04e-05	0.000374	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NT5C3A—bone cancer	3.02e-05	0.000371	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—MMP9—bone cancer	3.02e-05	0.000371	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ATF1—bone cancer	2.92e-05	0.000359	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MMP2—bone cancer	2.86e-05	0.000352	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KIT—bone cancer	2.85e-05	0.000351	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL3—bone cancer	2.85e-05	0.00035	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.75e-05	0.000338	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KIT—bone cancer	2.74e-05	0.000337	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—EGFR—bone cancer	2.66e-05	0.000327	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.65e-05	0.000326	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—GSTP1—bone cancer	2.62e-05	0.000322	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ENO2—bone cancer	2.59e-05	0.000319	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NT5C3A—bone cancer	2.58e-05	0.000317	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—DHFR—bone cancer	2.41e-05	0.000296	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NDUFA12—bone cancer	2.4e-05	0.000295	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.39e-05	0.000294	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ENO2—bone cancer	2.38e-05	0.000292	CbGpPWpGaD
Lidocaine—EGFR—Disease—TGFBR2—bone cancer	2.25e-05	0.000277	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GNA11—bone cancer	2.25e-05	0.000276	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—MDM2—bone cancer	2.25e-05	0.000276	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SMO—bone cancer	2.22e-05	0.000273	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—DHFR—bone cancer	2.2e-05	0.000271	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—MDM2—bone cancer	2.16e-05	0.000265	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MMP9—bone cancer	2.15e-05	0.000265	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GNA11—bone cancer	2.06e-05	0.000253	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CYP3A4—bone cancer	2.04e-05	0.000251	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—GNA11—bone cancer	2.03e-05	0.00025	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NT5C3A—bone cancer	1.99e-05	0.000245	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—JUN—bone cancer	1.95e-05	0.00024	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ENO2—bone cancer	1.92e-05	0.000236	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ATF1—bone cancer	1.89e-05	0.000232	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.88e-05	0.000231	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ENO2—bone cancer	1.87e-05	0.00023	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CYP3A4—bone cancer	1.87e-05	0.00023	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL3—bone cancer	1.84e-05	0.000226	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—DHFR—bone cancer	1.78e-05	0.000219	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GSTP1—bone cancer	1.74e-05	0.000214	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—DHFR—bone cancer	1.74e-05	0.000214	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GNA11—bone cancer	1.66e-05	0.000204	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KIT—bone cancer	1.66e-05	0.000204	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GNA11—bone cancer	1.63e-05	0.0002	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ENO2—bone cancer	1.62e-05	0.0002	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GSTP1—bone cancer	1.6e-05	0.000196	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.58e-05	0.000194	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TGFBR2—bone cancer	1.58e-05	0.000194	CbGpPWpGaD
Lidocaine—EGFR—Disease—KIT—bone cancer	1.53e-05	0.000189	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CYP3A4—bone cancer	1.51e-05	0.000185	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—DHFR—bone cancer	1.51e-05	0.000185	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IGF1R—bone cancer	1.48e-05	0.000182	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP3A4—bone cancer	1.47e-05	0.000181	CbGpPWpGaD
Lidocaine—EGFR—Disease—BRAF—bone cancer	1.44e-05	0.000177	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ENO2—bone cancer	1.41e-05	0.000174	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GNA11—bone cancer	1.41e-05	0.000173	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—bone cancer	1.36e-05	0.000167	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ENO2—bone cancer	1.33e-05	0.000164	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ENO2—bone cancer	1.32e-05	0.000162	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—DHFR—bone cancer	1.31e-05	0.000161	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MDM2—bone cancer	1.31e-05	0.000161	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSTP1—bone cancer	1.29e-05	0.000159	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP3A4—bone cancer	1.28e-05	0.000157	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.27e-05	0.000156	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTP1—bone cancer	1.26e-05	0.000155	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—DHFR—bone cancer	1.24e-05	0.000152	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GNA11—bone cancer	1.23e-05	0.000151	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—DHFR—bone cancer	1.23e-05	0.000151	CbGpPWpGaD
Lidocaine—EGFR—Disease—MDM2—bone cancer	1.21e-05	0.000149	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—bone cancer	1.17e-05	0.000143	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GNA11—bone cancer	1.16e-05	0.000142	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GNA11—bone cancer	1.15e-05	0.000141	CbGpPWpGaD
Lidocaine—EGFR—Immune System—JUN—bone cancer	1.14e-05	0.00014	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ENO2—bone cancer	1.13e-05	0.000139	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP3A4—bone cancer	1.11e-05	0.000137	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTP1—bone cancer	1.09e-05	0.000134	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KIT—bone cancer	1.07e-05	0.000132	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.05e-05	0.000129	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—DHFR—bone cancer	1.05e-05	0.000129	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.04e-05	0.000128	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.03e-05	0.000127	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—BRAF—bone cancer	1.01e-05	0.000124	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GNA11—bone cancer	9.79e-06	0.00012	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTP1—bone cancer	9.51e-06	0.000117	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—bone cancer	9.03e-06	0.000111	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTP1—bone cancer	8.96e-06	0.00011	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTP1—bone cancer	8.88e-06	0.000109	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP3A4—bone cancer	8.88e-06	0.000109	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.83e-06	0.000109	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ENO2—bone cancer	8.71e-06	0.000107	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MDM2—bone cancer	8.47e-06	0.000104	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—bone cancer	8.28e-06	0.000102	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—DHFR—bone cancer	8.08e-06	9.94e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTP1—bone cancer	7.59e-06	9.33e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GNA11—bone cancer	7.56e-06	9.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—JUN—bone cancer	7.36e-06	9.05e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—bone cancer	7.16e-06	8.8e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—bone cancer	6.68e-06	8.21e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—bone cancer	6.53e-06	8.03e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTP1—bone cancer	5.86e-06	7.2e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—bone cancer	5.65e-06	6.95e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—bone cancer	4.93e-06	6.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—bone cancer	4.86e-06	5.97e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—bone cancer	4.64e-06	5.71e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—bone cancer	4.6e-06	5.66e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—bone cancer	3.93e-06	4.84e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—bone cancer	3.03e-06	3.73e-05	CbGpPWpGaD
